Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Vasc Interv Radiol ; 33(6): 619-626.e1, 2022 06.
Artigo em Inglês | MEDLINE | ID: mdl-35150837

RESUMO

PURPOSE: To test the hypothesis that interventional radiologists (IRs) and neurointerventional (NI) physicians have similar outcomes of endovascular stroke thrombectomy (EVT), which could be used to improve the availability of thrombectomy. MATERIALS AND METHODS: Eight hospitals providing EVT performed by IRs and NI physicians at the same institution submitted sequential retrospective data limited to the era of modern devices. Good clinical outcomes (a 90-day modified Rankin score [mRS] of 0-2) and technically successful revascularization (a modified thrombolysis in cerebral infarction score of ≥2b) were compared between the specialties after adjusting for treating hospital, patient age, stroke severity, Alberta stroke program early computed tomography score, time from symptom onset to door, and clot location. Propensity score matching was used to compare the outcomes. A total of 1,009 patients were evaluated (622 treated by IRs and 387 treated by NI physicians). RESULTS: The median time from stroke onset to puncture was 245 versus 253 minutes (P = .49), the technically successful revascularization rate was 81.8% versus 82.4% (P = .81), and the good clinical outcome rate was 45.5% versus 50.1% (P = .16). After adjusting, the physician specialty was not a significant predictor of good clinical outcomes (odds ratio, 1.028; 95% confidence interval, 0.760-1.390; P = .86). After matching, an mRS of 0-2 was present in 47.7% of IR treated patients and 51.1% of NI treated patients (P = .366). CONCLUSIONS: There were no significant differences in the successful revascularization rate and good clinical outcomes between IRs and NI physicians. The outcomes of EVT performed by IRs were similar to those of EVT performed by NI physicians, as determined using previously published trials and registries. This may be useful for addressing coverage and access to stroke interventions.


Assuntos
Isquemia Encefálica , Procedimentos Endovasculares , Acidente Vascular Cerebral , Isquemia Encefálica/terapia , Procedimentos Endovasculares/efeitos adversos , Procedimentos Endovasculares/métodos , Humanos , Radiologistas , Estudos Retrospectivos , Acidente Vascular Cerebral/diagnóstico por imagem , Acidente Vascular Cerebral/cirurgia , Trombectomia/efeitos adversos , Trombectomia/métodos , Resultado do Tratamento
3.
Spine (Phila Pa 1976) ; 37(7): 544-50, 2012 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-21738093

RESUMO

STUDY DESIGN: Randomized, controlled, prospective (AAOS therapeutic level I) trial conducted under Food and Drug Administration Investigational Device Exemption hypothesized noninferiority of a novel bioactive composite material to polymethylmethacrylate (PMMA). OBJECTIVE: To determine the safety and efficacy of a new, nonresorbable bioactive composite (Cortoss) compared with PMMA, the standard treatment of vertebral compression fractures (VCFs). SUMMARY OF BACKGROUND DATA: Vertebroplasty with PMMA, the widely adopted treatment for VCFs nonresponsive to conservative care, provides effective, immediate pain relief, but the material has received criticism for its properties. A new bioactive composite material designed specifically for vertebroplasty showed promising results in animals and nonrandomized clinical studies and was subsequently compared with PMMA in a randomized study. This study represents the first prospective study evaluating vertebroplasty comparing PMMA with another material with 24-month follow-up. METHODS: Using 2:1 randomization, vertebroplasty was performed with Cortoss on 162 patients and PMMA on 94 patients. Inclusion criteria were painful osteoporotic VCFs with a visual analogue scale pain score of at least 50 mm on a 100-mm scale and at least 30% disability as measured by the Oswestry Disability Index. Evaluations at pretreatment, treatment day, and 7 posttreatment intervals out to 24 months included pain, disability, neurological status, adverse events, quality of life, patient satisfaction, analgesic use, and independently reviewed radiographs. RESULTS: Noninferiority of Cortoss relative to PMMA was observed, with Cortoss-treated patients experiencing significant pain relief at 3 months (P = 0.0395) and better maintenance or improvement in function at 24 months (P = 0.0299). Incidence of serious device-related adverse events was 4.3% in both groups; none were life threatening. CONCLUSION: Vertebroplasty using either Cortoss or PMMA provides effective, immediate, and lasting pain relief and prevents further loss of function. Both materials performed comparably at most time points; Cortoss demonstrated better results for pain reduction at 3 months and for function at 24 months.


Assuntos
Bis-Fenol A-Glicidil Metacrilato/uso terapêutico , Fraturas por Compressão/cirurgia , Polimetil Metacrilato/uso terapêutico , Fraturas da Coluna Vertebral/cirurgia , Vertebroplastia/instrumentação , Adulto , Idoso , Idoso de 80 Anos ou mais , Pesquisa Comparativa da Efetividade , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Medição da Dor , Estudos Prospectivos , Resultado do Tratamento , Vertebroplastia/métodos
4.
J Vasc Interv Radiol ; 20(3): 327-33, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19157897

RESUMO

PURPOSE: To determine the safety and feasibility of intraarterial stroke therapy for acute ischemic strokes at a community-based medical center. MATERIALS AND METHODS: This is a retrospective analysis of data gathered from consecutive stroke patients treated between June 2004 and April 2007. The following therapies were used to treat acute ischemic stroke within 6 hours of symptom onset: intraarterial thrombolytic drugs, intraarterial vasodilators, mechanical clot retrieval, intravascular stents, and angioplasty. The outcomes measured included posttherapy National Institutes of Health Stroke Score (NIHSS), neurologic function at 90 days graded according to the modified Rankin Scale (mRS), recanalization, symptomatic intracranial hemorrhage, and 90-day mortality. RESULTS: Eighty-three patients with a median baseline NIHSS of 17 (range, 3-30) were treated with intraarterial therapy. The median posttherapy NIHSS was 5 (range, 0-33). Forty-two patients (51%) [corrected] had an mRS score of 2 or less at 90 days. The recanalization rate was 76%. Five patients (6%) had symptomatic intracranial hemorrhage, and the 90-day mortality was 22%. CONCLUSIONS: The results of this review showed that an intraarterial therapeutic approach to acute ischemic stroke was feasible at a community-based heath center and demonstrated encouraging data for outcome and safety.


Assuntos
Prótese Vascular , Isquemia Encefálica/complicações , Isquemia Encefálica/terapia , Embolização Terapêutica/métodos , Stents , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/prevenção & controle , Vasodilatadores/administração & dosagem , Doença Aguda , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA